ADENOSCAN Drug Patent Profile

When do Adenoscan patents expire, and when can generic versions of Adenoscan launch?

Adenoscan is a drug marketed by Astellas and is included in one NDA.

The generic ingredient in ADENOSCAN is adenosine. There are twenty-six drug master file entries for this compound. Twelve suppliers are listed for this compound. Additional details are available on the adenosine profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Adenoscan

A generic version of ADENOSCAN was approved as adenosine by HIKMA on June 16^th, 2004.

Summary for ADENOSCAN

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	161
Clinical Trials:	10
Patent Applications:	4,209
DailyMed Link:	ADENOSCAN at DailyMed

Recent Clinical Trials for ADENOSCAN

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
NYU Langone Health	N/A
University of Utah	Early Phase 1
National Heart, Lung, and Blood Institute (NHLBI)	Early Phase 1

See all ADENOSCAN clinical trials

Paragraph IV (Patent) Challenges for ADENOSCAN

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
ADENOSCAN	Injection	adenosine	3 mg/mL, 20 mL and 30 mL vials	020059	1	2005-04-18

US Patents and Regulatory Information for ADENOSCAN

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Astellas	ADENOSCAN	adenosine	SOLUTION;INTRAVENOUS	020059-001	May 18, 1995		DISCN	Yes	No
Astellas	ADENOSCAN	adenosine	SOLUTION;INTRAVENOUS	020059-002	May 18, 1995		DISCN	Yes	No

Expired US Patents for ADENOSCAN

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Astellas	ADENOSCAN	adenosine	SOLUTION;INTRAVENOUS	020059-001	May 18, 1995
Astellas	ADENOSCAN	adenosine	SOLUTION;INTRAVENOUS	020059-002	May 18, 1995
Astellas	ADENOSCAN	adenosine	SOLUTION;INTRAVENOUS	020059-001	May 18, 1995

International Patents for ADENOSCAN

See the table below for patents covering ADENOSCAN around the world.

Country	Patent Number	Title	Estimated Expiration
Japan	2914454
European Patent Office	0275249	CONTINUOUS INTRAVENOUS INFUSION OF ADENOSINE TO HUMAN PATIENTS, A UNIT DOSAGE FORM OF ADENOSINE AND USE OF ADENOSINE FOR THE MANUFACTURE OF MEDICAMENTS
Germany	3586993
Japan	2535504
Germany	3590855

ADENOSCAN Market Analysis and Financial Projection Experimental

Market Dynamics and Financial Trajectory for Adenosine Injections (Adenoscan)

Market Overview

Adenosine injections, commonly known by the brand name Adenoscan, are crucial in the management of cardiac arrhythmias and other cardiovascular conditions. The market for these injections is experiencing significant growth driven by several key factors.

Rising Prevalence of Chronic Diseases

The increasing prevalence of chronic diseases such as cardiovascular diseases, cystic fibrosis, lung cancer, and atrial fibrillation is a major driver of the adenosine injection market. According to the American Heart Association, 40% of people in the U.S. will be affected by heart disease by 2030, which is expected to increase the number of cardiac surgeries and the demand for adenosine injections[1].

Technological Advancements and Innovations

Recent innovations in adenosine injection technology, such as prefilled syringes and improved delivery mechanisms, are enhancing the market. These advancements simplify administration, especially in high-pressure emergency scenarios, and have received global recognition for their user-friendly design[4].

Increased Healthcare Spending and Awareness

The aging population and increased healthcare spending worldwide are also driving the demand for adenosine injections. Rising awareness about cardiac conditions and the importance of timely interventions in emergency settings further contribute to market growth[4].

Market Segmentation

The adenosine injection market is segmented based on type, application, and end-user. The type segment includes dosage quantities of 6mg/2ml and 3mg/ml, with the 3mg/ml solution being widely used among pediatric patients and those on controlled sodium diets. In terms of application, cardiac surgery is expected to dominate the market, driven by the increasing number of myocardial perfusion scintigraphy procedures[1].

Regional Analysis

North America is expected to hold a dominant share of the market due to the rising number of people undergoing cardiac surgeries, an increasing geriatric population, and significant funding in healthcare. The Asia Pacific region is anticipated to be the fastest-growing market, driven by improved medical infrastructure, a large target population, and increased healthcare expenditure[1].

Financial Trajectory

The global adenosine injection market is projected to grow at a CAGR of 5.17% from 2024 to 2030, reaching a market size of US$ 2.59 billion by 2030. This growth is supported by the increasing demand for cardiac surgeries and the rising prevalence of chronic diseases[1].

Revenue Projections

• 2023 Market Size: US$ 1.82 billion
• 2030 Market Size: US$ 2.59 billion
• CAGR: 5.17% from 2024 to 2030[1].

Key Players and Competitive Landscape

The market is competitive, with key players including Torrent Laboratories, Sun Pharmaceuticals, Celon Laboratories, Pfizer, Teva Pharmaceuticals, and others. These companies are focusing on innovation, manufacturing, and global distribution channels to tap into the growing market[1].

Challenges and Restraints

Despite the positive growth trajectory, the market faces some challenges. Side effects associated with adenosine injections, such as triggering convulsions in patients, can hamper market growth. Therefore, careful monitoring of administration is crucial[1].

Regulatory Environment

Several governments have fast-tracked the approval of advanced adenosine injection products, ensuring timely access to life-saving treatments. Favorable regulatory frameworks and funding programs for orphan pharmaceuticals also support market growth[4].

Impact of Technological Innovations

Technological innovations, such as wearable devices capable of administering adenosine during emergencies, are revolutionizing emergency medicine. These advancements provide rapid relief and are ideal for emergency settings, further driving market growth[4].

Conclusion

The adenosine injection market, exemplified by products like Adenoscan, is poised for significant growth driven by the rising prevalence of chronic diseases, technological advancements, and increased healthcare spending. While the market faces some challenges related to side effects, the overall outlook is positive, with North America and the Asia Pacific region expected to be key drivers of growth.

Key Takeaways

• The global adenosine injection market is expected to grow at a CAGR of 5.17% from 2024 to 2030.
• The market is driven by the rising prevalence of chronic diseases and technological innovations.
• North America and the Asia Pacific region are expected to be major contributors to market growth.
• Cardiac surgery is the dominant application segment.
• Side effects associated with adenosine injections are a significant restraint.

FAQs

What is the primary use of adenosine injections in medical settings?

Adenosine injections are primarily used to treat paroxysmal supraventricular tachycardia (PSVT) and other life-threatening cardiac arrhythmias by slowing conduction through the AV node and restoring normal heart function[4].

Which region is expected to dominate the adenosine injection market?

North America is expected to hold a dominant share of the global adenosine injection market due to the rising number of people undergoing cardiac surgeries and an increasing geriatric population[1].

What are the key drivers of the adenosine injection market?

The key drivers include the rising prevalence of chronic diseases, technological advancements, increased healthcare spending, and growing awareness about cardiac conditions[1][4].

What are the potential side effects of adenosine injections?

Side effects of adenosine injections can include flushing, dizziness, chest discomfort, and in some cases, triggering convulsions in patients. These side effects are generally mild and short-lived but require careful monitoring[1][4].

How is the competitive landscape of the adenosine injection market?

The market is competitive with key players such as Torrent Laboratories, Sun Pharmaceuticals, Celon Laboratories, Pfizer, and Teva Pharmaceuticals. These companies are focusing on innovation, manufacturing, and global distribution channels[1].

Sources

1. Maximize Market Research: "Adenosine Injection Market - Industry Analysis, Forecast 2030"
2. ADENTRA Group: "ADENTRA Announces Annual and Fourth Quarter 2023 Results"
3. Market Research Intellect: "Adenosine Deaminase Deficiency Drugs Market Size and Forecast"
4. Market Research Intellect: "The Role of Adenosine Injections in Revolutionizing Emergency Medicine"